3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
9
Myelodysplastic Syndromes
7
Brain Neoplasms
7
Neoplasm Metastasis
6
Recurrence
5
Glioma
5
Glioblastoma
5
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Head and Neck Neoplasms
4
Sarcoma
3
Neoplasms
3
Leukemia
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Astrocytoma
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Neuroepithelial
2
Nasopharyngeal Carcinoma
2
Mouth Neoplasms
2
Melanoma
2
Diffuse Intrinsic Pontine Glioma
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Solid Tumor Malignancies
1
Interventions
Rituximab
259
Cyclophosphamide
238
Etoposide
114
Prednisone
97
Vincristine
96
Doxorubicin
96
Peripheral Blood Stem Cell Transplantation
95
fludarabine phosphate
87
Filgrastim
80
Cytarabine
61
Lenalidomide
60
Mycophenolic Acid
59
Melphalan
59
Radiotherapy
58
Busulfan
52
Cyclosporine
50
Carmustine
49
Whole-Body Irradiation
48
Tacrolimus
46
Methotrexate
42
Antilymphocyte Serum
38
Gemcitabine
33
Ifosfamide
32
Carboplatin
32
fludarabine
31
Dexamethasone
31
polatuzumab vedotin
29
Granulocyte Colony-Stimulating Factor
29
CT-P10
28
Methylprednisolone
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Large B-Cell, Diffuse
×
Valproic Acid
×
Clear all
NCT01622439
2018-03-12
VALFRID
Lund University Hospital
Phase 1/2
Completed
50 enrolled